Signaling Pathways in Osteoclast Differentiation
- PMID: 26865996
- PMCID: PMC4742606
- DOI: 10.4068/cmj.2016.52.1.12
Signaling Pathways in Osteoclast Differentiation
Abstract
Osteoclasts are multinucleated cells of hematopoietic origin that are responsible for the degradation of old bone matrix. Osteoclast differentiation and activity are controlled by two essential cytokines, macrophage colony-stimulating factor (M-CSF) and the receptor activator of nuclear factor-κB ligand (RANKL). M-CSF and RANKL bind to their respective receptors c-Fms and RANK to stimulate osteoclast differentiation through regulation of delicate signaling systems. Here, we summarize the critical or essential signaling pathways for osteoclast differentiation including M-CSF-c-Fms signaling, RANKL-RANK signaling, and costimulatory signaling for RANK.
Keywords: Bone and bones; Macrophage colony-stimulating factor; Osteoclasts; RANK ligand; Signal transduction.
Conflict of interest statement
Figures

Similar articles
-
Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.J Bone Miner Res. 2001 Nov;16(11):2074-81. doi: 10.1359/jbmr.2001.16.11.2074. J Bone Miner Res. 2001. PMID: 11697804
-
Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.Life Sci. 2007 Mar 13;80(14):1311-8. doi: 10.1016/j.lfs.2006.12.037. Epub 2007 Jan 23. Life Sci. 2007. PMID: 17306833
-
Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.Endocrinology. 2001 Aug;142(8):3656-62. doi: 10.1210/endo.142.8.8300. Endocrinology. 2001. PMID: 11459815
-
Mechanistic insight into osteoclast differentiation in osteoimmunology.J Mol Med (Berl). 2005 Mar;83(3):170-9. doi: 10.1007/s00109-004-0612-6. Epub 2005 Jan 26. J Mol Med (Berl). 2005. PMID: 15776286 Review.
-
The molecular understanding of osteoclast differentiation.Bone. 2007 Feb;40(2):251-64. doi: 10.1016/j.bone.2006.09.023. Epub 2006 Nov 13. Bone. 2007. PMID: 17098490 Review.
Cited by
-
In Silico Network Analysis of Ingredients of Cornus officinalis in Osteoporosis.Med Sci Monit. 2021 Apr 2;27:e929219. doi: 10.12659/MSM.929219. Med Sci Monit. 2021. PMID: 33795629 Free PMC article.
-
A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.Clin Transl Med. 2021 May;11(5):e392. doi: 10.1002/ctm2.392. Clin Transl Med. 2021. PMID: 34047464 Free PMC article.
-
Fucoxanthin Suppresses Osteoclastogenesis via Modulation of MAP Kinase and Nrf2 Signaling.Mar Drugs. 2021 Feb 27;19(3):132. doi: 10.3390/md19030132. Mar Drugs. 2021. PMID: 33673704 Free PMC article.
-
Infrapatellar fat pad adipose tissue-derived macrophages display a predominant CD11c+CD206+ phenotype and express genotypes attributable to key features of OA pathogenesis.Front Immunol. 2024 Feb 1;15:1326953. doi: 10.3389/fimmu.2024.1326953. eCollection 2024. Front Immunol. 2024. PMID: 38361943 Free PMC article.
-
RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells.Med Oncol. 2023 Mar 10;40(4):115. doi: 10.1007/s12032-023-01960-8. Med Oncol. 2023. PMID: 36897488 Free PMC article.
References
-
- Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292–304. - PubMed
-
- Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250–2261. - PubMed
-
- Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4:638–649. - PubMed
-
- Sherr CJ. Colony-stimulating factor-1 receptor. Blood. 1990;75:1–12. - PubMed
-
- Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345–357. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous